Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Liver X Receptor Identified as Therapeutic Target for Treatment of Parkinson's Disease

By BiotechDaily International staff writers
Posted on 06 Sep 2012
Print article
Neurologists seeking means to prevent or treat Parkinson's disease have found that a protein receptor expressed on the microglial cells that surround dopamine-producing neurons plays a critical role in preventing the development of the disease.

The receptor protein studied by investigators at the University of Houston (TX, USA) is liver X receptor beta (LXRbeta). The liver X receptors (nuclear receptor subfamily 1, group H, member 2), LXRalpha and LXRbeta, form a subfamily of the nuclear receptor superfamily and are key regulators of macrophage function, controlling transcriptional programs involved in lipid homeostasis and inflammation. The inducible LXRalpha is highly expressed in liver, adrenal gland, intestine, adipose tissue, macrophages, lung, and kidney, whereas LXRbeta is ubiquitously expressed.

To determine the function of LXRbeta in brain tissues the investigators genetically engineered a line of mice lacking the gene for synthesis of this receptor. These modified mice and a matching group of normal, wild type mice were then exposed to the drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is a neurotoxin that damages the brain in ways that closely mimic Parkinson's disease.

Results published in the July 23, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA (PNAS) revealed that the dopamine-producing neurons of the substantia nigra of the genetically engineered mice were much more severely affected by MPTP than were those of the wild type controls. In addition, the number of activated microglia and astrocytes was higher in the substantia nigra of the modified mice than in the controls. Administration of the LXR-activating drug GW3965 to MPTP-treated control mice protected against loss of dopamine-producing neurons and fibers projecting to the striatum, and resulted in fewer activated microglia and astroglia.

"LXRbeta performs an important function in the development of the central nervous system, and our work indicates that the presence of LXRbeta promotes the survival of dopaminergic neurons, which are the main source of dopamine in the central nervous system," said senior author Dr. Jan-Ake Gustafsson, professor of biosciences and nutrition at the University of Houston. "The receptor continues to show promise as a potential therapeutic target for this disease, as well as other neurological disorders."

"LXRbeta is not expressed in the dopamine-producing neurons, but instead in the microglia surrounding the neurons," said Dr. Gustafsson. "Microglia are the police of the brain, keeping things in order. In Parkinson's disease the microglia are overactive and begin to destroy the healthy neurons in the neighborhood of those neurons damaged by MPTP. LXRbeta calms down the microglia and prevents collateral damage. Thus, we have discovered a novel therapeutic target for treatment of Parkinson's disease."

Related Links:
University of Houston


Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.